Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04002661 · ClinicalTrials.gov registry record · Phase 2
Hypoactive Sexual Desire Disorder in Males
A Phase 2 study, sponsored by Mohit Khera.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT04002661 is a Phase 2 study that was terminated before completion, run by Mohit Khera. The registered enrollment target is 8 participants.
The verdict
NCT04002661, a Phase 2 study, was terminated before completion, sponsored by Mohit Khera.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the study drug will increase sexual desire in men with HSDD. Half of the participants will take ADDYI while the other half will receive a placebo (a look-alike pill with no medicine).
Interventions
- DRUG Placebo
- DRUG Flibanserin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-05-08 |
| Est. Completion | 2026-01-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04002661
The ClinicalTrials.gov registry entry for NCT04002661 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mohit Khera, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04002661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04002661 about?
NCT04002661 is a clinical study titled "Hypoactive Sexual Desire Disorder in Males". The purpose of this study is to determine if the study drug will increase sexual desire in men with HSDD. Half of the participants will take ADDYI while the other half will receive a placebo (a look-alike pill with no medicine).
What is the current status of trial NCT04002661?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2020-05-08. Estimated completion is 2026-01-23.
What interventions are being tested in trial NCT04002661?
The interventions under investigation include: Placebo (DRUG), Flibanserin (DRUG).
Who is sponsoring clinical trial NCT04002661?
This trial is sponsored by Mohit Khera, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.